302 patents
Page 13 of 16
Utility
Cell Lines and Methods for Increased Protein Production
25 Nov 20
The present technology relates generally to methods for increasing recombinant protein production in various cells lines.
ROBERT ROTH, LORENZ MAYR
Filed: 1 Oct 18
Utility
Pharmaceutical Compositions Comprising AZD9291
18 Nov 20
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Cindy FINNIE, Steven Anthony RAW, David WILSON
Filed: 3 Aug 20
Utility
Methods for Treating Chronic Obstructive Pulmonary Disease In an Enhanced Patient Population Using Benralizumab
18 Nov 20
Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Paul NEWBOLD, Ubaldo MARTIN, Maria JISON, Peter BARKER
Filed: 14 May 20
Utility
Inhalation device for powdered drugs
9 Nov 20
The invention refers to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when actuated by the patient.
Martin Herder, Gerhard Ludanek, Ingo Mett, Joachim Schmidt
Filed: 16 Jan 13
Utility
C
9 Nov 20
Jason Kettle, Stuart Pearson, Martin Packer, James Smith, Tudor Grecu
Filed: 4 Mar 19
Utility
NMDA antagonist prodrugs
26 Oct 20
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
Filed: 19 Jan 19
Utility
5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -One Derivatives and Their Use As Dual Inhibitors of Phosphatidylinositol 3-KINASE Delta & Gamma
30 Sep 20
Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
Filed: 20 Sep 17
Utility
Novel Inhibitors of Phosphatidylinositol 3-KINASE Gamma
23 Sep 20
Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
Filed: 8 Mar 17
Utility
Stable, Aqueous Formulations of Antibodies That Bind IL5 Receptor
23 Sep 20
The present invention relates to stable, aqueous antibody formulations.
William LEACH, Rachael LEWUS, James MCGIVNEY, Kelcy NEWELL, Kevin Douglas STEWART
Filed: 24 Mar 20
Utility
Biomarker of PNPLA3 Expression
23 Sep 20
The present disclosure relates to a novel biomarker for measuring PNPLA3 gene expression and methods of using the novel biomarker for treating, preventing, or ameliorating a disease associated with PNPLA3.
Mathias LILJEBLAD
Filed: 17 Dec 19
Utility
Combination of a BTK Inhibitor and an Inhibitor or CDK9 to Treat Cancer
16 Sep 20
The present invention relates to combination of a BTK inhibitor and an inhibitor of CDK9 for use in the treatment of cancer in a subject.
Scott BOIKO, Justin CIDADO, Lisa DREW, Teresa PROIA, Maryann SAN MARTIN
Filed: 23 Sep 18
Utility
Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
14 Sep 20
The present invention relates to the use of myeloperoxidase inhibitors (MPO) inhibitors for the treatment of multiple system atrophy.
Hakan Eriksson, Werner Poewe
Filed: 29 Aug 18
Utility
[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
7 Sep 20
Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
Filed: 31 Jul 19
Utility
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
26 Aug 20
The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
Filed: 6 Nov 18
Utility
Pharmaceutical Compositions
12 Aug 20
The present application relates to solid pharmaceutical compositions and solid dosage forms containing them which comprise oils as their active pharmaceutical ingredient.
Christian VON CORSWANT, Romain BORDES, Simon Peter Michael HJELM JONASSON
Filed: 5 Jul 17
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES As Dipeptidyl Peptidase 1 Inhibitors
5 Aug 20
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
Filed: 21 Apr 20
Utility
Orally disintegrating tablets
3 Aug 20
The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient.
Farhan Abdel Karim Mohammad Al Husban, Lars Håkan Christer Glad, Jenny Malin Christina Hallstein, Andrea Jane Moir, Michael Peter Thompson
Filed: 19 Apr 17
Utility
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
29 Jul 20
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene.
Darren Anthony, Edward Cross, Catherine Anne Eberlein
Filed: 1 Apr 15
Utility
Chemical Compounds
29 Jul 20
Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
Filed: 27 Jan 20
Utility
Selective Estrogen Receptor Down-Regulators
29 Jul 20
Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
Filed: 28 Jan 20